Rabbit anti vaccinia virus antibody recognizes vaccinia virus purified virions. It reacts with Lister and NYCBOH strains of Vaccinia.
It does not cross react with Parainfluenza (1-3), RSV, Adenovirus, Influenza A+B, or HSV.
- Target Species
- Product Form
- Purified IgG - liquid
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.1% Sodium Azide (NaN3)
- Vaccinia virus, New York City Board of Health (NYCBOH) strain.
- Approx. Protein Concentrations
- IgG concentration 4 mg/ml
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted.
Avoid repeated freezing and thawing as this may denature the antibody.
Should this product contain a precipitate we recommend microcentrifugation before use.
- 12 months from date of despatch
- For research purposes only
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Applications of Vaccinia Virus antibody
|Immunohistology - Frozen
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using the appropriate negative/positive controls.
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Application Based External Images
Immunohistology - Frozen
Product Specific References
References for Vaccinia Virus antibody
Hornemann, S. et al. (2003) Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L.
J Virol. 77 (15): 8394-407.
Manuel, E.R. et al. (2010) Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses.
Virology. 2010 403: 155-62.
Staib, C. et al. (2004) Construction and isolation of recombinant MVA.
Methods Mol Biol. 269: 77-100.
Olszewska, W. et al. (2004) Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins.
Vaccine. 23: 215-21.
Vogel, T.U. et al. (2003) Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.
J Virol. 77: 13348-60.
Buttigieg, K.R. et al. (2014) A Novel Vaccine against Crimean-Congo Haemorrhagic Fever Protects 100% of Animals against Lethal Challenge in a Mouse Model.
PLoS One. 9(3):e91516.